UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/676,270	10/02/2003	Hiroki Sakakibara	7412/80657	3446	
	7590 12/23/200 TABIN & FLANNER	EXAMINER			
P. O. BOX 184 WASHINGTON	- -	SAMALA, JAGADISHWAR RAO			
WASHINGTO	N, DC 20030		ART UNIT	PAPER NUMBER	
			1618		
			MAIL DATE	DELIVERY MODE	
			12/23/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/676,270	SAKAKIBARA ET AL.	
Examiner	Art Unit	
JAGADISHWAR R. SAMALA	1618	

	JAGADISHWAR R. SAMALA	1618					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress				
THE REPLY FILED <u>21 October 2008</u> FAILS TO PLACE THIS A	APPLICATION IN CONDITION FOR	R ALLOWANCE.					
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperfor Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A replies: (1) an amendment, affidavited al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire a Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(dvisory Action, or (2) the date set forth a later than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE f).	g date of the final rejection FIRST REPLY WAS FII	on. LED WITHIN TWO				
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	ension and the corresponding amount on hortened statutory period for reply origing than three months after the mailing date	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as				
NOTICE OF APPEAL							
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed w AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
3. The proposed amendment(s) filed after a final rejection, be	out prior to the date of filing a brief	will not be entered be	causo				
(a) They raise new issues that would require further cor	nsideration and/or search (see NOT		cause				
(c) They are not deemed to place the application in bet appeal; and/or	**	lucing or simplifying tl	ne issues for				
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	ected claims.					
4. The amendments are not in compliance with 37 CFR 1.116	21 See attached Notice of Non-Co	mnliant Amendment (PTOL-324)				
5. Applicant's reply has overcome the following rejection(s):		inpliant Americanent (101-02-7.				
	S. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the						
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of				
Claim(s) allowed: <u>NONE</u> . Claim(s) objected to: <u>NONE</u> . Claim(s) rejected: <u>1-9</u> .							
Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 							
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a				
10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER							
 11. The request for reconsideration has been conside because: See Continuation Sheet. 	ered but does NOT place the applic	ation in condition for a	allowance				
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (13. ☐ Other:	PTO/SB/08) Paper No(s)						
_							
/Michael G. Hartley/ Supervisory Patent Examiner, Art Unit 1618	Jagadishwar R Samala Examiner Art Unit: 1618						

Application No.

Continuation of 11. does NOT place the application in condition for allowance because: For the reasons of the record, the Office Action mailed on 04/21/2008 is maintained. Applicant argues that either Nishmura or Ritter teaches or suggests the vascularization therapy as recited in the instant claims. This argument is not persuasive because: Nishmura teaches that Carbon dioxide bathing wherein the cutaneous blood in the immersed skin (wherein thermal effects of carbon dioxide bathing could have direct action on vascular smooth muscles), thus interpretation of vascular therapy (see abstract and page 337). As evidenced by Hidekazu Irie et al (Circulation, 2005, 111: 1523-1529) that carbon dioxide bathing of ischemic hindlimb causes the induction of local VEGF synthesis, resulting in an NO-dependent neocapillary formation associated with mobilization of endothelial progenitor cells. Taken together, this accumulated evidence may raise the possibility that the carbon dioxide enriched water bathing therapy enhances regional blood perfusion by increasing new vessel formation (see methods and results, pages 1523-1524). Applicant should note that this is not an introduction of new reference. Just supportive evidence for "rebuttal" purpose only.